NANOLEK
About us
  • Team
  • History
  • Strategy, mission, values
  • Honors and awards
  • Education and CSR
  • Occupational Safety and Health
  • Partners
R&D
Products
  • Vaccines
  • Biotechnology products
  • Chemical products
  • Contract manufacture
  • Other products
Manufacturing
  • Biopharmaceuticals
  • Solid dosage forms
  • Quality control
  • Certificates
Press center
  • Company news
    • Company news
    • Photo gallery
    • Media kit
    • Media contacts
  • Photo gallery
  • Media kit
  • Media contacts
Careers
  • Vacancies
    • Vacancies
    • Corporate culture
  • Corporate culture
Contacts
Ещё
    Ask a question
    info@nanolek.ru
    Moscow, Butyrsky Val, 68, bldg. 1 Baker Plaza Business Center, 2nd floor, office 24
    • Vkontakte
    • Facebook
    • Instagram
    • YouTube
    EN | RU
    NANOLEK
    About us
    • Team
    • History
    • Strategy, mission, values
    • Honors and awards
    • Education and CSR
    • Occupational Safety and Health
    • Partners
    R&D
    Products
    • Vaccines
    • Biotechnology products
    • Chemical products
    • Contract manufacture
    • Other products
    Manufacturing
    • Biopharmaceuticals
    • Solid dosage forms
    • Quality control
    • Certificates
    Press center
    • Company news
    • Photo gallery
    • Media kit
    • Media contacts
    Careers
    • Vacancies
    • Corporate culture
    Contacts
      NANOLEK
      About us
      • Team
      • History
      • Strategy, mission, values
      • Honors and awards
      • Education and CSR
      • Occupational Safety and Health
      • Partners
      R&D
      Products
      • Vaccines
      • Biotechnology products
      • Chemical products
      • Contract manufacture
      • Other products
      Manufacturing
      • Biopharmaceuticals
      • Solid dosage forms
      • Quality control
      • Certificates
      Press center
      • Company news
      • Photo gallery
      • Media kit
      • Media contacts
      Careers
      • Vacancies
      • Corporate culture
      Contacts
        NANOLEK
        EN | RU
        NANOLEK
        • About us
          • Back
          • About us
          • Team
          • History
          • Strategy, mission, values
          • Honors and awards
          • Education and CSR
          • Occupational Safety and Health
          • Partners
        • R&D
        • Products
          • Back
          • Products
          • Vaccines
          • Biotechnology products
          • Chemical products
          • Contract manufacture
          • Other products
        • Manufacturing
          • Back
          • Manufacturing
          • Biopharmaceuticals
          • Solid dosage forms
          • Quality control
          • Certificates
        • Press center
          • Back
          • Press center
          • Company news
            • Back
            • Company news
            • Company news
            • Photo gallery
            • Media kit
            • Media contacts
          • Photo gallery
          • Media kit
          • Media contacts
        • Careers
          • Back
          • Careers
          • Vacancies
            • Back
            • Vacancies
            • Vacancies
            • Corporate culture
          • Corporate culture
        • Contacts
        info@nanolek.ru
        Moscow, Butyrsky Val, 68, bldg. 1 Baker Plaza Business Center, 2nd floor, office 24
        • Vkontakte
        • Facebook
        • Instagram
        • YouTube

        Press center

        • Press center
        • Company news
        • NANOLEK's General Director Takes Part in the INNOPROM Session: Innovations in Pharmaceuticals and Medicine: Overcoming Barriers in the Development and Creation of Solutions
        • Company news
        • Photo gallery
        • Media kit
        • Media contacts

        NANOLEK's General Director Takes Part in the INNOPROM Session: Innovations in Pharmaceuticals and Medicine: Overcoming Barriers in the Development and Creation of Solutions

        27.10.2020




        The participants discussed the critical issues of changes that are taking place in the coronavirus reality: challenges for manufacturers in the development of innovative products and relevant government support measures for them, the impact of the pandemic on attitudes to innovation on the part of business and regulators, as well as how the interaction of fundamental science and production is going to develop.

        The meeting was moderated by Vadim Tarasov (I.M.Sechenov First Moscow State Medical University). Among the participants in the session were: Dmitry Galkin (Deputy Director of the Development Department of the Pharmaceutical and Medical Industry of the Ministry of Industry and Trade of Russia), Dmitry Akhaev (Deputy Dean of the Faculty of Biology for Innovation at M.V.Lomonosov Moscow State University), Mikhail Nekrasov (NANOLEK's General Director), Dmitry Kudlai (General Director of Generium, JSC), Andrey Ivashchenko (Chairman of the Board of Directors of NP TsVT KhimRar) and others.

        The pandemic has highlighted some weaknesses in health systems worldwide. Due to this fact, we are continually analysing and making conclusions to take practical steps to improve communication among key stakeholders in the health industry. Simultaneously, the ongoing changes have sharpened and revealed one of the most important pharmaceutical and medical sectors' objectives - creating innovative products.

        Vadim Tarasov, Director of the Institute of Pharmacy and Translational Medicine of the Sechenov First MSMU: "The pandemic has shown that Russia, like other leading countries of the world, can generate its innovative products thanks to its research school. In the shortest possible time, our companies, the industry leaders, have brilliantly made a whole range of Russian medicines that allow our state and citizens to feel protected and receive adequate high-quality preventive treatment. This applies to the developments that have been made, among other things, by the participants in our discussion today. This also applies to vaccines in the field of which our country is at the forefront.

        Now we are faced with the central question of creating a unified system in the Russian Federation that would make it possible to build truly innovative products. Moreover, there are already practical steps in this direction. Several large-scale projects for the development of science are being launched in the country, and a strategic academic leadership program is being launched. It is based on the cooperation of research institutions, scientific centres of Russian universities, which, in close connection with industrial, pharmaceutical enterprises, must build a chain for developing and implementing innovative products in the pharmaceutical and medical industries."

        Currently, we are all going through a severe ordeal. We are witnessing how the world's leading countries could create reasonably quickly innovative medications that are needed for the treatment and prevention of Covid-19, including vaccines. Finding and producing vaccines is difficult and expensive, although essential for national security and export potential.

        NANOLEK is one of the leaders in the production of paediatric vaccines. The participants were interested in hearing a comment on how the company sees development opportunities in terms of increasing its stability, what questions are there for the government and regulators about setting up the production of domestic vaccines, introducing the most promising developments, and what steps must be taken to perform the transition to innovation.

        Mikhail Nekrasov, NANOLEK's General Director: "NANOLEK is an innovative company in the first place. We initially decided that we are an enterprise that is engaged in production as well as scientific research. Our company's development strategy is to combine scientific competencies and production resources for the implementation of joint projects to develop innovative immunobiological medicines; cooperation with leading scientific institutions. I mean collaborative work with the M.P.Chumakov Scientific Centre, and with Skolkovo. This approach helps develop science and ultimately not only creates but also produces original medicines.

        Finding vaccines is not an easy job, but we understand that a biotech enterprise has two parts: sterile filling and the finished form production. The second is the production of the antigens themselves.

        Thanks to the Ministry of Industry and Trade - its Pharma 2020 program has given impetus to develop innovative products in the industry. Now we discuss with them and the Ministry of Health the need to create additional experimental-industrial capacities that will make it possible to bring scientific developments into industrial production.

        In this case, we are following the path of agreements with leading institutions. From laboratory development to production - it is a big step. We started by making the first step - a pure form (vaccine production: Polimilex®, an inactivated poliomyelitis vaccine, and Pentaxim®, a vaccine against five infections). We have begun to form a recombinant site (production of the antigens themselves) to produce vaccines on a full cycle. We follow the path of agreements with leading scientific institutions as an industrial partner. The coronavirus infection has shown that our country could quickly mobilize and produce a vaccine. Still, it is almost impossible to make the required number of doses (about 150 million) in 2-3 months because there are no such facilities in Russia. I am firmly in favour of innovation, but at the same time, for the creation of the required number of capacities for the production of biotechnological products."




        Subscribe to our
        email newsletter

        Subscribe
        Назад к списку
        About us
        Team
        History
        Strategy, mission, values
        Honors and awards
        Education and CSR
        Occupational Safety and Health
        Partners
        Press center
        Company news
        Photo gallery
        Media kit
        Media contacts
        Manufacturing
        Biopharmaceuticals
        Solid dosage forms
        Quality control
        Certificates
        Compliance
        Privacy policy
        Pharmacovigilance
        Subscribe
        info@nanolek.ru
        Moscow, Butyrsky Val, 68, bldg. 1 Baker Plaza Business Center, 2nd floor, office 24
        • Vkontakte
        • Facebook
        • Instagram
        • YouTube
        PRIVACY POLICY
        © 2021